Trials / Active Not Recruiting
Active Not RecruitingNCT00463814
AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies
A Phase I, Open-Label, Multi-centre Study to Assess the Safety, Tolerability and Pharmacokinetics of a Solid Oral Dosage Formulation (Capsule) of AZD6244 in Patients With Advanced Solid Malignancies
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 58 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of the study is to assess the safety, tolerability and pharmacokinetics of a capsule of AZD6244 in participants with advanced solid malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD6244 | Participants will receive single oral dose of AZD6244 as described in arm description. |
Timeline
- Start date
- 2007-03-08
- Primary completion
- 2008-06-17
- Completion
- 2025-12-31
- First posted
- 2007-04-20
- Last updated
- 2025-11-13
Locations
4 sites across 3 countries: United States, Netherlands, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT00463814. Inclusion in this directory is not an endorsement.